IPO Boutique

Alcobra Ltd. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Alcobra Ltd. , and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Alcobra Ltd. ADHD - $10.00-$12.00 $8.00 $8.253.125 million5/22/2013
Aegis Capital Corp
Co-Manager(s):
Sunrise Securities Corp.,Feltl & Company, Inc
Health Care
Filing(s):

Filed 2013-01-14



Alcobra Ltd. Quote & Chart - Click for current quote - ADHD

About Alcobra Ltd. (adapted from Alcobra Ltd. prospectus):
They are an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder, or ADHD.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "ADHD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved